Duality Advisers LP Acquires New Position in Enovis Co. (NYSE:ENOV)

Duality Advisers LP acquired a new stake in shares of Enovis Co. (NYSE:ENOV) during the fourth quarter, HoldingsChannel reports. The fund acquired 5,291 shares of the company’s stock, valued at approximately $296,000.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Enovis by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,897,449 shares of the company’s stock worth $258,242,000 after purchasing an additional 51,319 shares during the period. Diamond Hill Capital Management Inc. increased its stake in Enovis by 9.9% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 2,429,173 shares of the company’s stock worth $128,090,000 after purchasing an additional 219,659 shares during the period. DAVENPORT & Co LLC increased its stake in Enovis by 12.6% in the 4th quarter. DAVENPORT & Co LLC now owns 1,879,425 shares of the company’s stock worth $105,920,000 after purchasing an additional 210,358 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Enovis by 0.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,031,710 shares of the company’s stock worth $57,796,000 after purchasing an additional 4,274 shares during the period. Finally, Principal Financial Group Inc. increased its stake in Enovis by 0.8% in the 3rd quarter. Principal Financial Group Inc. now owns 832,415 shares of the company’s stock worth $43,893,000 after purchasing an additional 6,353 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ENOV has been the topic of a number of analyst reports. Canaccord Genuity Group lifted their price target on Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Wells Fargo & Company lifted their price target on Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. UBS Group started coverage on Enovis in a research report on Monday, January 22nd. They issued a “buy” rating and a $75.00 price objective on the stock. Stephens started coverage on Enovis in a research report on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 price objective on the stock. Finally, William Blair started coverage on Enovis in a research report on Wednesday, January 3rd. They issued an “outperform” rating on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Enovis presently has a consensus rating of “Buy” and an average target price of $75.43.

Enovis Trading Up 0.2 %

NYSE ENOV opened at $55.23 on Friday. The firm has a market capitalization of $3.03 billion, a PE ratio of -90.54 and a beta of 1.97. The stock’s 50 day moving average is $59.95 and its 200 day moving average is $55.48. Enovis Co. has a twelve month low of $43.04 and a twelve month high of $66.14. The company has a quick ratio of 1.16, a current ratio of 2.43 and a debt-to-equity ratio of 0.14.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.03. The company had revenue of $455.00 million for the quarter, compared to analysts’ expectations of $444.34 million. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. The firm’s revenue for the quarter was up 11.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.72 earnings per share. Research analysts forecast that Enovis Co. will post 2.58 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.